Codexis Inc., a leader in enzymatic solutions for therapeutics manufacturing, has entered into an agreement with Axolabs, a division of LGC Group and a prominent oligonucleotide Contract Research Development and Manufacturing Organization (CRDMO). Under this agreement, Axolabs will evaluate Codexis' ECO Synthesis® Manufacturing Platform, an innovative enzymatic solution for scalable RNA manufacturing. The collaboration aims to facilitate more efficient, sustainable, and cost-effective production of oligonucleotide therapeutics and could lead to future licensing and broader adoption of Codexis’ platform. Both companies emphasize their commitment to advancing high-quality oligonucleotide medicines and expanding access globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN57502) on January 07, 2026, and is solely responsible for the information contained therein.